2020
Head and neck squamous cell carcinoma
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature Reviews Disease Primers 2020, 6: 92. PMID: 33243986, PMCID: PMC7944998, DOI: 10.1038/s41572-020-00224-3.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaHuman papillomavirusCell carcinomaOral cavityLarynx cancerAJCC/UICC staging systemEGFR monoclonal antibody cetuximabLate stage HNSCCLeast toxic therapyImmune checkpoint inhibitorsHPV-positive HNSCCTreatment of recurrentHPV-positive diseaseOral cavity cancerUICC staging systemHPV-negative HNSCCPre-malignant lesionsDegree of dysplasiaMonoclonal antibody cetuximabUnresectable diseaseCheckpoint inhibitorsPrimary chemoradiotherapyCytotoxic chemotherapyMost patients
2018
Overview: The Pathobiology of Head and Neck Cancer
Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2018, 1-5. DOI: 10.1007/978-3-319-78762-6_1.Peer-Reviewed Original ResearchNeck cancerHPV-negative diseaseImmune checkpoint blockadeSquamous cell cancerHigh recurrence ratePathobiology of headEarly-stage cancerTumor suppressor gene mutationsSuppressor gene mutationsMultimodality therapyCheckpoint blockadeCytotoxic chemotherapyMetastatic diseaseAdvanced cancerCell cancerRecurrence rateHuman papillomavirusDevastating cancerStage cancerSubglottic larynxCancerPersonalized therapyGene mutationsPatientsTherapy
2013
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabDrug DesignDrug Resistance, NeoplasmErbB ReceptorsHead and Neck NeoplasmsHistone Deacetylase InhibitorsHumansMolecular Targeted TherapyPapillomaviridaeProtein Kinase InhibitorsProto-Oncogene Proteins c-metReceptor, ErbB-2Signal TransductionTreatment OutcomeConceptsHPV-negative headNeck cancerHuman papillomavirusEGFR inhibitionSingle-agent cetuximabLow cure rateMonoclonal antibody cetuximabActive therapyCytotoxic chemotherapyDisease survivalCure rateMechanisms of resistanceAntibody cetuximabResponse rateCetuximabEGFRNovel targetReceptor tyrosine kinasesCancerTherapyHistone deacetylaseChemotherapyHabitual exposureModest effectNuclear functions
2010
Antibody-Based Therapies for Solid Tumors
Shanbhag S, Burtness B. Antibody-Based Therapies for Solid Tumors. Cancer Growth And Progression 2010, 245-256. DOI: 10.1007/978-90-481-9704-0_13.Peer-Reviewed Original ResearchSide effectsHER2-overexpressing breast cancerStandard cytotoxic chemotherapyCell lung cancerEGFR antibody cetuximabAntibody-based therapiesExcess side effectsAnti-VEGF antibodyMechanism of actionMetastatic settingCytotoxic chemotherapyMetastatic colorectalLung cancerColorectal carcinomaBreast cancerAntibody cetuximabVEGF antibodySolid tumorsAntibody trastuzumabClinical useMonoclonal antibodiesCancer therapeuticsCancerAntibodiesBevacizumab